Quick Answer
bioAffinity Technologies, Inc. reported Operating Income of -$10.57 million for fiscal year 2025.
bioAffinity Technologies, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$10.57M | -18.1% |
| 2024 | -$8.95M | -12.3% |
| 2023 | -$7.97M | -98.8% |
| 2022 | -$4.01M | -81.8% |
| 2021 | -$2.21M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.29M | -16.2% | +8.9% |
| June 30, 2025 | -$2.52M | -20.5% | +4.2% |
| March 31, 2025 | -$2.63M | -35.1% | -33.1% |
| September 30, 2024 | -$1.97M | +14.0% | +5.5% |
| June 30, 2024 | -$2.09M | -17.4% | -7.3% |
| March 31, 2024 | -$1.95M | -24.9% | +15.2% |
| September 30, 2023 | -$2.29M | -135.1% | -29.0% |
| June 30, 2023 | -$1.78M | -159.9% | -14.1% |
- bioAffinity Technologies, Inc. showed a decrease of -18.1% in Operating Income compared to the prior fiscal year.
- Over the 2021–2025 period, bioAffinity Technologies, Inc.’s operating income has declined by 379.1% (from -$2.21 million to -$10.57 million).
- The most recent figure is from bioAffinity Technologies, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: